Verrica Pharmaceuticals Inc. (VRCA): Nasdaq/NYSE listing notice — Verrica receives Nasdaq deficiency notice; stock below $1 for 30 days, 180-day cure period until July 23, 2025

Verrica Pharmaceuticals Inc.

Nasdaq notified Verrica on Jan 24, 2025 that bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5450(a)(1).
Company has 180 days (until July 23, 2025) to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, Verrica may transfer to Nasdaq Capital Market by paying $5,000 fee and meeting other standards except bid price.
Company is considering options including reverse stock split and application to transfer to Nasdaq Capital Market.
No immediate impact on listing; delisting risk if compliance not achieved within cure periods.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Verrica Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Verrica Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 23, 2025, to regain compliance

View on SEC.gov

Browse all listing & compliance notices →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-017264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.